Dr. Neil B. Desai

Radiation Oncology
6202 Harry Hines Blvd, 
Dallas, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
6202 Harry Hines Blvd, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Neil Desai is a Radiation Oncologist in Dallas, Texas. Dr. Desai is rated as an Experienced provider by MediFind in the treatment of Esophageal Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, Mycosis Fungoides, and Prostatectomy.

His clinical research consists of co-authoring 91 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in TX
Hospital Affiliations
UT Of Texas Southwestern University Hospital - William P. Clements Jr.
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS
6202 Harry Hines Blvd, Dallas, TX 75235
Other Locations
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS
6201 Harry Hines Blvd, Dermatology, Dallas, TX 75390
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS
2280 Inwood Rd, Dallas, TX 75235
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS
5201 Harry Hines Blvd, Dallas, TX 75235

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Enrollment Status: Recruiting
Publish Date: November 10, 2025
Intervention Type: Drug, Radiation
Study Drugs: Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Relugolix, Triptorelin
Study Phase: Phase 3
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Enrollment Status: Completed
Publish Date: December 09, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Bicalutamide, Docetaxel, Flutamide, Goserelin acetate, Leuprolide acetate, Nilutamide
Study Phase: Phase 2/Phase 3
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (With Enzalutamide) in Patients With Post-Prostatectomy PSA Recurrences With Aggressive Disease Features
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (With Enzalutamide) in Patients With Post-Prostatectomy PSA Recurrences With Aggressive Disease Features
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Radiation, Drug
Study Drugs: Enzalutamide, Bicalutamide, GnRH analog
Study Phase: Phase 2
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: November 07, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 3
An Open-label, Controlled, Randomized Phase 3 Trial Evaluating 12-month Kidney Function in Highly Sensitized (cPRA ≥99.9%) Kidney Tx Patients With Positive XM Against a Deceased Donor, Comparing Desensitization Using Imlifidase With SoC
An Open-label, Controlled, Randomized Phase 3 Trial Evaluating 12-month Kidney Function in Highly Sensitized (cPRA ≥99.9%) Kidney Tx Patients With Positive XM Against a Deceased Donor, Comparing Desensitization Using Imlifidase With SoC
Enrollment Status: Completed
Publish Date: July 16, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Imlifidase, IVIg, Anti-CD20 Antibodies, Eculizumab
Study Phase: Phase 3
A Multi-Center Trial of Androgen Suppression With Abiraterone aCetate, LEuprolide, PARP Inhibition and Stereotactic Body Radiotherapy (ASCLEPIuS): A Phase I/2 Trial in High Risk and Node Positive Prostate Cancer
A Multi-Center Trial of Androgen Suppression With Abiraterone aCetate, LEuprolide, PARP Inhibition and Stereotactic Body Radiotherapy (ASCLEPIuS): A Phase I/2 Trial in High Risk and Node Positive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2025
Intervention Type: Drug, Radiation
Study Drugs: Niraparib, Leuprolide, Abiraterone acetate
Study Phase: Phase 1/Phase 2
A Phase II Trial of Stereotactic Ablative Radiation Therapy (SAbR) for Patients With Oligo-progressive Renal Cell Cancer (RCC).
A Phase II Trial of Stereotactic Ablative Radiation Therapy (SAbR) for Patients With Oligo-progressive Renal Cell Cancer (RCC).
Enrollment Status: Completed
Publish Date: July 17, 2024
Intervention Type: Radiation
Study Phase: Phase 2
Phase I Trial of Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome
Phase I Trial of Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome
Enrollment Status: Withdrawn
Publish Date: April 22, 2020
Intervention Type: Radiation, Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

91 Total Publications

Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.
Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: November 10, 2025
Similar Doctors
Experienced in Esophageal Cancer
Dr. Aurelie Garant
Radiation Oncology
Experienced in Esophageal Cancer
Dr. Aurelie Garant
Radiation Oncology

University Of Texas Southwestern Medical Center At Dallas

5323 Harry Hines Blvd, 
Dallas, TX 
 (0.6 miles away)
216-648-0600
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Aurelie Garant is a Radiation Oncologist in Dallas, Texas. Dr. Garant is rated as an Advanced provider by MediFind in the treatment of Esophageal Cancer. Her top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Esophageal Cancer, and Adult Soft Tissue Sarcoma.

Experienced in Esophageal Cancer
Dr. Shahed N. Badiyan
Radiation Oncology
Experienced in Esophageal Cancer
Dr. Shahed N. Badiyan
Radiation Oncology

University Of Texas Southwestern Medical Center At Dallas

2280 Inwood Rd, 
Dallas, TX 
 (0.4 miles away)
214-645-8525
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shahed Badiyan is a Radiation Oncologist in Dallas, Texas. Dr. Badiyan is rated as a Distinguished provider by MediFind in the treatment of Esophageal Cancer. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Posterior Fossa Tumor, and Primitive Neuroectodermal Tumor (PNET).

Experienced in Esophageal Cancer
Dr. Nina N. Sanford
Radiation Oncology
Experienced in Esophageal Cancer
Dr. Nina N. Sanford
Radiation Oncology

University Of Texas Southwestern Medical Center At Dallas

2280 Inwood Rd, 
Dallas, TX 
 (0.4 miles away)
214-645-8525
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nina Sanford is a Radiation Oncologist in Dallas, Texas. Dr. Sanford is rated as an Advanced provider by MediFind in the treatment of Esophageal Cancer. Her top areas of expertise are Anal Cancer, Gastroesophageal Junction Cancer, Pancreatic Cancer, Colonoscopy, and Endoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Desai's expertise for a condition
ConditionClose
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile